vs
BridgeBio Pharma, Inc.(BBIO)与Resolute Holdings Management, Inc.(RHLD)财务数据对比。点击上方公司名可切换其他公司
BridgeBio Pharma, Inc.的季度营收约是Resolute Holdings Management, Inc.的1.3倍($154.2M vs $117.7M),Resolute Holdings Management, Inc.净利率更高(-1.5% vs -126.2%,领先124.8%),Resolute Holdings Management, Inc.自由现金流更多($189.2M vs $-56.5M)
本文提供的介绍实际对应 Brent Saunders 的个人履历,而非BridgeBio Pharma, Inc. 的企业信息。Brent Saunders是美国生物制药行业高管与企业家,目前担任博士伦公司董事长兼首席执行官,曾主导参与多起大型医药并购交易,同时涉足特殊目的收购公司领域,在医疗板块拥有丰富行业经验。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业,核心业务布局于非洲地区,目前运营两座金矿,分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿,专注于黄金资源的勘探、开采及相关运营管理工作。
BBIO vs RHLD — 直观对比
营收规模更大
BBIO
是对方的1.3倍
$117.7M
净利率更高
RHLD
高出124.8%
-126.2%
自由现金流更多
RHLD
多$245.7M
$-56.5M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $154.2M | $117.7M |
| 净利润 | $-194.6M | $-1.7M |
| 毛利率 | 94.7% | 55.7% |
| 营业利润率 | -90.5% | 30.2% |
| 净利率 | -126.2% | -1.5% |
| 营收同比 | 2521.2% | — |
| 净利润同比 | 27.2% | — |
| 每股收益(稀释后) | $-1.00 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
BBIO
RHLD
| Q4 25 | $154.2M | $117.7M | ||
| Q3 25 | $120.7M | $120.9M | ||
| Q2 25 | $110.6M | $119.6M | ||
| Q1 25 | $116.6M | $103.9M | ||
| Q1 24 | $211.1M | — | ||
| Q2 22 | $73.7M | — |
净利润
BBIO
RHLD
| Q4 25 | $-194.6M | $-1.7M | ||
| Q3 25 | $-184.9M | $-231.0K | ||
| Q2 25 | $-183.8M | $-611.0K | ||
| Q1 25 | $-169.6M | $-3.4M | ||
| Q1 24 | $-36.2M | — | ||
| Q2 22 | $-2.6M | — |
毛利率
BBIO
RHLD
| Q4 25 | 94.7% | 55.7% | ||
| Q3 25 | 94.6% | 59.0% | ||
| Q2 25 | 96.7% | 57.5% | ||
| Q1 25 | 97.7% | 52.5% | ||
| Q1 24 | 99.7% | — | ||
| Q2 22 | 99.1% | — |
营业利润率
BBIO
RHLD
| Q4 25 | -90.5% | 30.2% | ||
| Q3 25 | -120.3% | 34.3% | ||
| Q2 25 | -121.4% | 34.0% | ||
| Q1 25 | -89.5% | 24.7% | ||
| Q1 24 | 0.2% | — | ||
| Q2 22 | -108.7% | — |
净利率
BBIO
RHLD
| Q4 25 | -126.2% | -1.5% | ||
| Q3 25 | -153.2% | -0.2% | ||
| Q2 25 | -166.2% | -0.5% | ||
| Q1 25 | -145.4% | -3.2% | ||
| Q1 24 | -17.1% | — | ||
| Q2 22 | -3.5% | — |
每股收益(稀释后)
BBIO
RHLD
| Q4 25 | $-1.00 | $-0.20 | ||
| Q3 25 | $-0.95 | $-0.03 | ||
| Q2 25 | $-0.95 | $-0.07 | ||
| Q1 25 | $-0.88 | $-0.39 | ||
| Q1 24 | $-0.20 | — | ||
| Q2 22 | $-0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $570.1M | $205.5M |
| 总债务越低越好 | $2.0B | $169.8M |
| 股东权益账面价值 | $-2.1B | $6.5M |
| 总资产 | $936.0M | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势,按日历期对齐
现金及短期投资
BBIO
RHLD
| Q4 25 | $570.1M | $205.5M | ||
| Q3 25 | $643.0M | $148.0M | ||
| Q2 25 | $756.9M | $99.9M | ||
| Q1 25 | $540.6M | $71.0M | ||
| Q1 24 | $519.7M | — | ||
| Q2 22 | $688.6M | — |
总债务
BBIO
RHLD
| Q4 25 | $2.0B | $169.8M | ||
| Q3 25 | $2.0B | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q1 24 | — | — | ||
| Q2 22 | — | — |
股东权益
BBIO
RHLD
| Q4 25 | $-2.1B | $6.5M | ||
| Q3 25 | $-1.9B | $10.8M | ||
| Q2 25 | $-1.8B | $9.6M | ||
| Q1 25 | $-1.6B | $8.9M | ||
| Q1 24 | $-1.0B | — | ||
| Q2 22 | $-1.0B | — |
总资产
BBIO
RHLD
| Q4 25 | $936.0M | $333.4M | ||
| Q3 25 | $998.3M | $293.2M | ||
| Q2 25 | $1.1B | $253.3M | ||
| Q1 25 | $881.6M | $214.3M | ||
| Q1 24 | $849.3M | — | ||
| Q2 22 | $862.2M | — |
负债/权益比
BBIO
RHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q1 24 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-56.4M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $-56.5M | $189.2M |
| 自由现金流率自由现金流/营收 | -36.6% | 160.8% |
| 资本支出强度资本支出/营收 | 0.0% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $313.2M |
8季度趋势,按日历期对齐
经营现金流
BBIO
RHLD
| Q4 25 | $-56.4M | $196.1M | ||
| Q3 25 | $-109.6M | $59.6M | ||
| Q2 25 | $-80.7M | $48.9M | ||
| Q1 25 | $-199.2M | $18.4M | ||
| Q1 24 | $-219.5M | — | ||
| Q2 22 | $-30.5M | — |
自由现金流
BBIO
RHLD
| Q4 25 | $-56.5M | $189.2M | ||
| Q3 25 | $-110.0M | $58.6M | ||
| Q2 25 | $-81.3M | $47.5M | ||
| Q1 25 | — | $17.8M | ||
| Q1 24 | $-220.2M | — | ||
| Q2 22 | $-32.9M | — |
自由现金流率
BBIO
RHLD
| Q4 25 | -36.6% | 160.8% | ||
| Q3 25 | -91.2% | 48.5% | ||
| Q2 25 | -73.5% | 39.7% | ||
| Q1 25 | — | 17.1% | ||
| Q1 24 | -104.3% | — | ||
| Q2 22 | -44.6% | — |
资本支出强度
BBIO
RHLD
| Q4 25 | 0.0% | 5.8% | ||
| Q3 25 | 0.4% | 0.8% | ||
| Q2 25 | 0.5% | 1.2% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q1 24 | 0.3% | — | ||
| Q2 22 | 3.3% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图